Episode Overview

Join us for an in-depth discussion on andexanet, exploring its role in reversing Factor Xa inhibitors and the latest insights from the 77th CTGTAC Meeting.

Session Timeline

7:00-7:05 – Introduction

• Welcome and topic overview
• Introduction to the andexanet debate
• FDA approval implications

7:05-7:20 – ANNEXA-I Trial Review

• Key findings and outcomes
• Interactive audience polling
• Discussion of safety concerns

7:20-7:40 – CTGTAC Meeting Insights

• Expert panel discussions
• Clinical implications
• Patient selection considerations

7:40-7:50 – Live Q&A Session

• Audience questions
• Expert responses

7:50-7:55 – Closing Remarks

• Key takeaways
• Future considerations

Interactive Elements

• Live polling throughout the session
• Real-time Q&A opportunities
• Case discussion participation
• Clinical scenario analysis